Armata Pharmaceuticals (ARMP) Cash from Investing Activities Growth (1y) (2014 - 2026)
Armata Pharmaceuticals (ARMP) Cash from Investing Activities Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 90.55% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 91.53% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -41.67% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.90% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -157.08% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -589.38% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -89.24% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 26.37% |
| 10 | Armata Pharmaceuticals | 182.82 Mn | 158.82 Mn | - | 88.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 88.59% |
| Mar 31, 2026 | 36.36% |
| Dec 31, 2025 | -167.53% |
| Sep 30, 2025 | 28.82% |
| Jun 30, 2025 | 89.09% |
| Mar 31, 2025 | 60.40% |
| Dec 31, 2024 | 103.22% |
| Sep 30, 2024 | 90.32% |
| Jun 30, 2024 | -515.32% |
| Mar 31, 2024 | 87.56% |
| Dec 31, 2023 | -625.27% |
| Sep 30, 2023 | -171.41% |
| Jun 30, 2023 | 80.46% |
| Mar 31, 2023 | -751.69% |
| Dec 31, 2022 | 299.56% |
| Sep 30, 2022 | -122.34% |
| Jun 30, 2022 | -479.59% |
| Mar 31, 2022 | 20.81% |
| Dec 31, 2021 | 37.70% |
| Sep 30, 2021 | -618.52% |